A phase I clinical trial is the first research monitored by the Food and Drug Administration that demonstrates the potential of regenerative therapy for hypoplastic left heart syndrome (HLHS) through collecting, processing and injecting an infant’s own stem cells directly into the heart at the time of surgery.
Click here for original story, Stem cell therapy furthers research for infants with hypoplastic left heart syndrome
Source: ScienceDaily